These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 29184)

  • 1. Clinical assessment of dopamine receptor blockade.
    Sedvall G; Bjerkenstedt L; Lindström L; Wode-Helgodt B
    Life Sci; 1978 Aug; 23(5):425-9. PubMed ID: 29184
    [No Abstract]   [Full Text] [Related]  

  • 2. The relationship between clinical and biochemical changes following neuroleptic treatment in schizophrenia.
    Cooper SJ; Leahey W; Liddle J; King DJ
    Schizophr Res; 1990; 3(4):261-7. PubMed ID: 1703780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variability of response to neuroleptics in schizophrenia: clinical, pharmacologic, and neuroendocrine correlates.
    Gelder M; Kolakowska T
    Compr Psychiatry; 1979; 20(5):397-408. PubMed ID: 39704
    [No Abstract]   [Full Text] [Related]  

  • 4. Neuroendocrinological and biochemical effects of chronic neuroleptic treatment.
    Hippius H; Ackenheil M; Müller-Spahn F
    Adv Biochem Psychopharmacol; 1985; 40():9-13. PubMed ID: 2862769
    [No Abstract]   [Full Text] [Related]  

  • 5. Dopamine and schizophrenia.
    Crow TJ; Johnstone EC; Longden A; Owen F
    Adv Biochem Psychopharmacol; 1978; 19():301-9. PubMed ID: 29450
    [No Abstract]   [Full Text] [Related]  

  • 6. The dopamine hypothesis of schizophrenia revisited.
    van Kammen DP
    Psychoneuroendocrinology; 1979 Jan; 4(1):37-46. PubMed ID: 39306
    [No Abstract]   [Full Text] [Related]  

  • 7. [Etiology of schizophrenia: neurochemical aspects].
    de las Cuevas Castresana C; González de Rivera JL
    Neurologia; 1994 Feb; 9(2):54-9. PubMed ID: 7515627
    [No Abstract]   [Full Text] [Related]  

  • 8. Down-regulation of central dopamine receptors in schizophrenia.
    Zemlan FP; Hitzemann RJ; Hirschowitz J; Garver DL
    Am J Psychiatry; 1985 Nov; 142(11):1334-7. PubMed ID: 2865903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Changes in the CSF levels of monoamine metabolites in 102 chronic schizophrenic patients following probenecid before and after neuroleptic medication].
    Chen YF
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1984 Oct; 17(5):273-7. PubMed ID: 6085683
    [No Abstract]   [Full Text] [Related]  

  • 10. Melperone in the treatment of schizophrenia.
    Bjerkenstedt L
    Acta Psychiatr Scand Suppl; 1989; 352():35-9. PubMed ID: 2479227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Examining the dopamine hypotheses of schizophrenia and of mania using the prolactin response to antipsychotic drugs.
    Silverstone T; Cookson J
    Neuropharmacology; 1983 Apr; 22(4):539-41. PubMed ID: 6134252
    [No Abstract]   [Full Text] [Related]  

  • 12. Plasma homovanillic acid, serum anti-D1 and anti-D2 receptor activity, and psychopathology in chronic schizophrenia.
    Koshikawa H; Suzuki E; Kanba S; Nibuya M; Ishizuki T; Kohno H; Kinoshita N; Shintani F; Yagi G; Nakaki T
    Yakubutsu Seishin Kodo; 1991 Feb; 11(1):79-81. PubMed ID: 1679276
    [No Abstract]   [Full Text] [Related]  

  • 13. Cerebrospinal fluid studies of monoamine metabolism in schizophrenia.
    van Kammen DP; Peters J; van Kammen WB
    Psychiatr Clin North Am; 1986 Mar; 9(1):81-97. PubMed ID: 2421272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma HVA, neuroleptics, and dopaminergic plasticity.
    Dávila R
    Biol Psychiatry; 1989 Jan; 25(1):1-3. PubMed ID: 2563229
    [No Abstract]   [Full Text] [Related]  

  • 15. Perspectives on a time-dependent model of neuroleptic action.
    Pickar D
    Schizophr Bull; 1988; 14(2):255-68. PubMed ID: 2904694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships between clinical and biochemical effects of melperone and thiothixene in psychotic women.
    Bjerkenstedt L; Gullberg B; Härnryd C; Sedvall G
    Arch Psychiatr Nervenkr (1970); 1979; 227(3):181-92. PubMed ID: 94992
    [No Abstract]   [Full Text] [Related]  

  • 17. Relationship between dopamine D2 receptor occupancy, clinical response, and drug and monoamine metabolites levels in plasma and cerebrospinal fluid. A pilot study in patients suffering from first-episode schizophrenia treated with quetiapine.
    Nikisch G; Baumann P; Kiessling B; Reinert M; Wiedemann G; Kehr J; Mathé AA; Piel M; Roesch F; Weisser H; Schneider P; Hertel A
    J Psychiatr Res; 2010 Sep; 44(12):754-9. PubMed ID: 20176367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Problem of neuronal reception and the dopamine hypothesis of schizophrenia].
    Lideman RR; Zlobina GP; Mukhin AG
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1980; 80(5):762-9. PubMed ID: 6106337
    [No Abstract]   [Full Text] [Related]  

  • 19. Dopamine and schizophrenia.
    Crow TJ; Deakin JF; Johnstone EC; Longden A
    Lancet; 1976 Nov; 2(7993):1027. PubMed ID: 62251
    [No Abstract]   [Full Text] [Related]  

  • 20. Neuroleptics, dopamine, and schizophrenia.
    Pickar D
    Psychiatr Clin North Am; 1986 Mar; 9(1):35-48. PubMed ID: 2870480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.